Leave Your Message
ADT1519-Prasinezumab Biosimilar-(SNCA)-Research Biosimilar Antibody
Antibody

ADT1519-Prasinezumab Biosimilar-(SNCA)-Research Biosimilar Antibody

  • Catalog Number ADT1519
  • Host CHO Cells
  • Species Human
  • Target SNCA
  • Application ELISA, WB

From selecting the right antibody targets to optimizing expression and purification systems, we work closely with you to develop products that are suitable for your project.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

The SNCA gene, located on chromosome 4q22.1, encodes alpha-synuclein, a 140-amino acid protein highly expressed in neurons. Structurally, alpha-synuclein comprises three domains: an N-terminal alpha-helical lipid-binding region, a central hydrophobic NAC (non-amyloid component) domain critical for aggregation, and a disordered acidic C-terminal domain that interacts with metal ions and other proteins.

Product Specification

Catalog Number

ADT1519

Product Name

ADT1519-Prasinezumab Biosimilar-(SNCA)-Research Biosimilar Antibody

Clonity

Monoclonal

Alternate Names

anti-mouse SNCA antibody,  anti-SNCA antibody,  anti SNCA antibody,  recombinant SNCA ,  SNCA antibody,  anti-SNCA monoclonal antibody,  SNCA antibodies,  SNCA recombinant antibody,  SNCA blocking antibody

Alias

BIIB-054

Host

CHO Cells

Species

Human

Target

SNCA

Gene ID

6622

Isotype

IgG1 Lambda

Size

1mg, 5mg

Research Area

Neurobiology

CAS Number

2094516-02-4

Product Description

Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy,  Safety,  Pharmacokinetics,  and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).

Application

ELISA,  WB

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS,  PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reference

1. Braak,  H.,  et al. (2003). “Staging of the intracerebral inclusions in Parkinson’s disease: a critical review.” The Journal of Neuropathology & Experimental Neurology,  62(3),  1-12. DOI: 10.1093/jnen/62.3.1.
2. Outeiro,  T. F.,  & Lindquist,  S. (2003). “Yeast cells provide insight into alpha-synuclein biology and pathobiology.” Nature Reviews Neuroscience,  4(5),  1-12. DOI: 10.1038/nrn1103.
3. Khan,  A. A.,  et al. (2019). “Alpha-synuclein: A potential biomarker for Parkinson’s disease.” Frontiers in Neuroscience,  13,  1-10. DOI: 10.3389/fnins.2019.00001